世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の遅発性ジスキネジア治療市場 2019-2023年

Global Tardive Dyskinesia Treatment Market 2019-2023

IRTNTR30055

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
113

サマリー

この調査レポートは世界の遅発性ジスキネジア治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Tardive Dyskinesia
Tardive dyskinesia is the involuntary movement of face and body as a side effect of using antipsychotic drugs for the treatment of mental disorders such as schizophrenia, bipolar disorder, and other brain conditions.
Technavio’s analysts forecast the Global Tardive Dyskinesia Treatment Market to grow at a CAGR of 4.44% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the tardive dyskinesia treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of tardive dyskinesia across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, tardive dyskinesia treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Merck
- Neurocrine Biosciences
- Novartis
- Teva Pharmaceutical
Market driver
- Increasing use of antipsychotic drugs across the globe
- For a full, detailed list, view our report

Market challenge
- Lack of awareness
- For a full, detailed list, view our report

Market trend
- Increasing R&D on VMAT2 inhibitors
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.




目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- AUSTEDO and INGREZZA - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- F. Hoffmann-La Roche
- Merck
- Neurocrine Biosciences
- Novartis
- Teva Pharmaceutical
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO

-
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2018
Exhibit 06: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 07: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 08: Five forces analysis 2018
Exhibit 09: Five forces analysis 2023
Exhibit 10: Bargaining power of buyers
Exhibit 11: Bargaining power of suppliers
Exhibit 12: Threat of new entrants
Exhibit 13: Threat of substitutes
Exhibit 14: Threat of rivalry
Exhibit 15: Market condition - Five forces 2018
Exhibit 16: Product - Market share 2018-2023 (%)
Exhibit 17: Comparison by product
Exhibit 18: AUSTEDO and INGREZZA - Market size and forecast 2018-2023 ($ millions)
Exhibit 19: AUSTEDO and INGREZZA - Year-over-year growth 2019-2023 (%)
Exhibit 20: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Others - Year-over-year growth 2019-2023 (%)
Exhibit 22: Market opportunity by product
Exhibit 23: Customer landscape
Exhibit 24: Market share by geography 2018-2023 (%)
Exhibit 25: Geographic comparison
Exhibit 26: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 28: Top 3 countries in Americas
Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in APAC
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Molecules in late-stage development
Exhibit 38: Recent approvals by US FDA
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: F. Hoffmann-La Roche - Vendor overview
Exhibit 46: F. Hoffmann-La Roche - Business segments
Exhibit 47: F. Hoffmann-La Roche - Organizational developments
Exhibit 48: F. Hoffmann-La Roche - Segment focus
Exhibit 50: F. Hoffmann-La Roche - Key offerings
Exhibit 51: F. Hoffmann-La Roche - Key customers
Exhibit 52: Merck - Vendor overview
Exhibit 53: Merck - Business segments
Exhibit 54: Merck - Organizational developments
Exhibit 55: Merck - Segment focus
Exhibit 56: Merck - Geographic focus
Exhibit 57: Merck - Key offerings
Exhibit 58: Merck - Key customers
Exhibit 59: Neurocrine Biosciences - Vendor overview
Exhibit 60: Neurocrine Biosciences - Organizational developments
Exhibit 61: Neurocrine Biosciences - Key offerings
Exhibit 62: Neurocrine Biosciences - Key customers
Exhibit 63: Novartis - Vendor overview
Exhibit 64: Novartis - Business segments
Exhibit 65: Novartis - Organizational developments
Exhibit 66: Novartis - Segment focus
Exhibit 67: Novartis - Geographic focus
Exhibit 68: Novartis - Key offerings
Exhibit 69: Novartis - Key customers
Exhibit 70: Teva Pharmaceutical - Vendor overview
Exhibit 71: Teva Pharmaceutical - Business segments
Exhibit 72: Teva Pharmaceutical - Organizational developments
Exhibit 73: Teva Pharmaceutical - Segment focus
Exhibit 75: Teva Pharmaceutical - Key offerings
Exhibit 76: Teva Pharmaceutical - Key customer
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る